RxDoctor Payments Data

Grant Hsing, MD

Family Medicine · Cumming, GANPI 1568684322

Payments from drug & device makers

$1,790in general payments, 2019–2025

Across 144 payments — averaging $12.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$374
  • AbbVie$351
  • Pfizer$192
  • Lilly USA, LLC$188
  • AstraZeneca$179
  • Amgen$122
  • plus $386 from 13 others

What the payments were for

  • Food & beverage$1,75798%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk30$374
AbbVie(2 entities)48$351
Pfizer10$192
Lilly USA, LLC12$188
AstraZeneca11$179
Amgen(2 entities)6$122
Boehringer Ingelheim7$97
Merck5$63
GSK4$59
Nalpropion Pharmaceuticals LLC2$32
Medtronic1$22
Sanofi-aventis U.S. LLC1$18
Novartis1$16
Kowa Pharmaceuticals America, Inc.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Exact Sciences1$13
Amarin Pharma, Inc.1$13
Zyla Life Sciences, Inc.1$12
Aytu Biopharma, Inc.1$12

How this compares

$1,790 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$115,078
Medicare patients
294
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$137,949
MounjaroTirzepatide44$68,061
RybelsusSemaglutide21$42,343
JanuviaSitagliptin Phosphate30$34,538
JardianceEmpagliflozin20$32,134
EliquisApixaban31$29,684
TrulicityDulaglutide17$26,718
FarxigaDapagliflozin Propanediol14$19,355
Repatha SureclickEvolocumab14$16,029
Tresiba Flextouch U-200Insulin Degludec12$9,719
Fenofibrate19$8,883
SynthroidLevothyroxine Sodium81$8,175
Gabapentin150$3,322
Albuterol Sulfate HfaAlbuterol Sulfate72$3,094
Atorvastatin Calcium316$2,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$374$180,292102 claims
Lilly USA, LLCMounjaro, Trulicity$188$94,77861 claims
MerckJanuvia$63$34,53830 claims
Boehringer IngelheimJardiance$97$32,13420 claims
PfizerEliquis$192$29,68431 claims
AstraZenecaFarxiga$179$19,35514 claims
AbbVieSynthroid$351$8,17581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →